BLSM Stock News & Catalysts – BlossomHill Therapeutics

FEATURED

BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC

New

Alignment with the US Food and Drug Administration on 50 mg twice daily as the recommended Phase 2 dose for BH-30643 SOLARA-2, the Phase 2 portion of the SOLARA trial, designed with registrational intent to evaluate

Summary

Nov 9, 2026, 7:00 AM ·Globe Newswire

RECENT

BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting

SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative

Nov 4, 2026, 7:00 AM ·Globe Newswire

BlossomHill Therapeutics to Present at Guggenheim’s 3rd Annual Healthcare Innovations Conference

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative

Nov 3, 2026, 7:00 AM ·Globe Newswire

BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer

SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative

Oct 22, 2026, 7:00 AM ·Globe Newswire

BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer

Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1

Sep 28, 2026, 7:00 AM ·Globe Newswire

BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results

Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering Announced FDA Fast Track designation for BH-30643 for the treatment of advanced EGFR C797S-positive NSCLC SAN

Sep 18, 2026, 7:00 AM ·Globe Newswire

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat population with no

Sep 15, 2026, 7:00 AM ·Globe Newswire

BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative

Sep 3, 2026, 7:00 AM ·Globe Newswire

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer

Data to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797S BH-30643 was recently granted Fast Track designation by

Sep 1, 2026, 7:00 AM ·Globe Newswire

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative

Aug 18, 2026, 7:00 AM ·Globe Newswire

BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering

SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., ("BlossomHill Therapeutics"), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to

Aug 6, 2026, 8:07 PM ·Globe Newswire

BlossomHill Therapeutics, Inc. BLSM · News